{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:48:47Z","timestamp":1792705727624,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013327","name":"Lundbeck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.eplepsyres.2019.106182","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T11:35:52Z","timestamp":1564572952000},"page":"106182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Pharmacometrics of clobazam in pediatrics: Prediction of effective clobazam doses for Dravet syndrome"],"prefix":"10.1016","volume":"157","author":[{"given":"Dwain","family":"Tolbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-May","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ene I.","family":"Ette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eplepsyres.2019.106182_bib0005","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1460-9592.2011.03536.x","article-title":"Tips and traps analyzing pediatric PK data","volume":"21","author":"Anderson","year":"2011","journal-title":"Paediatr. Anaesth."},{"issue":"9242","key":"10.1016\/j.eplepsyres.2019.106182_bib0010","first-page":"1638","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial","volume":"356","author":"Chiron","year":"2000","journal-title":"STICLO Study Group. Lancet."},{"issue":"5","key":"10.1016\/j.eplepsyres.2019.106182_bib0015","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1528-1167.2008.01935.x","article-title":"Clobazam in the treatment of Lennox-Gastaut syndrome","volume":"50","author":"Conry","year":"2009","journal-title":"Epilepsia."},{"issue":"6","key":"10.1016\/j.eplepsyres.2019.106182_bib0020","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00003088-199937060-00004","article-title":"Cytochrome P450 3A: ontogeny and drug disposition","volume":"37","author":"de Wildt","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2019.106182_bib0025","series-title":"(cannabidiol). Full Prescribing Information","author":"Epidiolex","year":"2018"},{"issue":"4","key":"10.1016\/j.eplepsyres.2019.106182_bib0030","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11095-005-2499-5","article-title":"Data supplementation: a pharmacokinetic\/pharmacodynamic knowledge creation approach for characterizing an unexplored region of the response surface","volume":"22","author":"Ette","year":"2005","journal-title":"Pharm. Res."},{"issue":"11","key":"10.1016\/j.eplepsyres.2019.106182_bib0035","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1124\/dmd.32.11.1279","article-title":"In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19","volume":"32","author":"Giraud","year":"2004","journal-title":"Drug Metab. Dispos."},{"issue":"9","key":"10.1016\/j.eplepsyres.2019.106182_bib0040","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","article-title":"Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children","volume":"45","author":"Johnson","year":"2006","journal-title":"Clin. Pharmacokinet."},{"issue":"suppl 14","key":"10.1016\/j.eplepsyres.2019.106182_bib0045","doi-asserted-by":"crossref","first-page":"P1.260","DOI":"10.1212\/WNL.84.14_supplement.P1.260","article-title":"Clobazam for Dravet syndrome: designing a clinical study using pharmacokinetic\/pharmacodynamic modeling [abstract]","volume":"84","author":"Lee","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.eplepsyres.2019.106182_bib0050","first-page":"262","article-title":"Developmental pharmacokinetics in pediatric populations","volume":"19","author":"Lu","year":"2014","journal-title":"J. Pediatr. Pharmacol. Ther."},{"issue":"15","key":"10.1016\/j.eplepsyres.2019.106182_bib0055","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/WNL.0b013e318232de76","article-title":"Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome","volume":"77","author":"Ng","year":"2011","journal-title":"Neurology."},{"key":"10.1016\/j.eplepsyres.2019.106182_bib0060","series-title":"Clobazam Investigator\u2019s Brochure, Version 4.0.","author":"Ovation Pharmaceuticals","year":"2009"},{"issue":"14","key":"10.1016\/j.eplepsyres.2019.106182_bib0065","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1212\/WNL.0b013e31826d5ec0","article-title":"Efficacy of antiepileptic drugs in adults predicts efficacy in children: a systematic review","volume":"79","author":"Pellock","year":"2012","journal-title":"Neurology."},{"issue":"7","key":"10.1016\/j.eplepsyres.2019.106182_bib0070","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1124\/dmd.115.068593","article-title":"Hepatic cytochrome P450 activity, abundance, and expression throughout human development","volume":"44","author":"Sadler","year":"2016","journal-title":"Drug Metab. Dispos."},{"issue":"7","key":"10.1016\/j.eplepsyres.2019.106182_bib0075","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40262-014-0140-7","article-title":"A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data","volume":"53","author":"Salem","year":"2014","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.eplepsyres.2019.106182_bib0080","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10928-012-9241-9","article-title":"First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development","volume":"39","author":"Strougo","year":"2012","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"3","key":"10.1016\/j.eplepsyres.2019.106182_bib0085","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/jcph.603","article-title":"Drug-metabolism mechanism: knowledge-based population pharmacokinetic approach for characterizing clobazam drug-drug interactions","volume":"56","author":"Tolbert","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2019.106182_bib0090","series-title":"Guidance for Industry: Population Pharmacokinetics","author":"US Department of Health and Human Services","year":"1999"},{"issue":"suppl 1","key":"10.1016\/j.eplepsyres.2019.106182_bib0095","first-page":"41S","article-title":"Kinetics and metabolism of clobazam in animals and man","volume":"7","author":"Volz","year":"1979","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.eplepsyres.2019.106182_bib0100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40272-016-0171-7","article-title":"Pharmacotherapy for Dravet syndrome","volume":"18","author":"Wallace","year":"2016","journal-title":"Paediatr. Drugs"},{"issue":"S2","key":"10.1016\/j.eplepsyres.2019.106182_bib0105","first-page":"M1479","article-title":"Bioavailability of oral clobazam tablets relative to oral clobazam solution following 20-mg doses in healthy volunteers","volume":"12","author":"Walzer","year":"2010","journal-title":"AAPS J."},{"issue":"suppl 3","key":"10.1016\/j.eplepsyres.2019.106182_bib0110","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1017\/cjn.2016.249","article-title":"Treatment of Dravet syndrome","volume":"43","author":"Wirrell","year":"2016","journal-title":"Can. J. Neurol. Sci."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121119301755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121119301755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:42:42Z","timestamp":1760276562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121119301755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":22,"alternative-id":["S0920121119301755"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.106182","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacometrics of clobazam in pediatrics: Prediction of effective clobazam doses for Dravet syndrome","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.106182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106182"}}